chAIron

EXPANDING THE KNOWLEDGE FRONTIER OF MOLECULES WITH ARTIFICIAL AND HUMAN INTELLIGENCE

DELIVERING INNOVATION IN INDICATION STRATEGY

At chAIron we combine artificial and human intelligence to expand the boundaries of molecular knowledge, revolutionizing therapeutic development and optimizing asset potential and value.

Founded in 2023 in Switzerland by professionals with a background in clinical research, data science, and finance with extensive experience in the Life Sciences and Financial Services industries.

ANALYSIS AND ADVISORY OF COMPANY ASSETS

Empowered by cutting-edge technology, our scientific and business experts leverage real-world data, literature, omics, and market insights to create a complete strategic roadmap of company assets.

We seek to help ClinDev and BizDev teams make well-informed decisions about their programs. Our goal is to form collaborative partnerships with our clients, share risks, and work together towards success.

WE FOCUS ON INDICATION DISCOVERY AND ASSET VALUE MAXIMISATION

Indication Discovery: Our AI-driven analysis verifies the known science and can unlock new indications for novel and existing mechanism-of-action to expand the potential of the asset.

Maximizing Asset Value: We assess molecules with a data-driven approach, guiding strategic decisions on the program’s development based on scientific viability, technical feasibility, and market impact.

EXPANDING THE KNOWLEDGE FRONTIER OF MOLECULES WITH ARTIFICIAL AND HUMAN INTELLIGENCE

DELIVERING INNOVATION IN INDICATION STRATEGY

ANALYSIS AND ADVISORY OF COMPANY ASSETS

WE FOCUS ON INDICATION DISCOVERY AND ASSET VALUE MAXIMISATION

CONTACT

Expanding the knowledge frontier of molecules to de-risk drug development, drive asset value, and improve probabilities of positive patient outcomes.

Rue de la Grotte 6, 1003 Lausanne, Switzerland